| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD83 |
| Uniprot No | Q01151 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-143aa |
| 氨基酸序列 | MSRGLQLLLL SCAYSLAPAT PEVKVACSED VDLPCTAPWD PQVPYTVSWV KLLEGGEERM ETPQEDHLRG QHYHQKGQNG SFDAPNERPY SLKIRNTTSC NSGTYRCTLQ DPDGQRNLSG KVIL |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD83重组蛋白的3篇代表性文献的简要概括：
1. **文献名称**：Soluble CD83 suppresses T-cell activation by inhibiting dendritic cell maturation
**作者**：Fujimoto Y, et al.
**摘要**：该研究探讨了可溶性CD83重组蛋白对树突状细胞(DC)成熟及T细胞活化的调控作用，发现其通过阻断DC表面CD83分子与配体结合，抑制DC成熟并减少促炎因子分泌，从而降低T细胞反应性。
2. **文献名称**：Recombinant CD83 modulates alloimmune responses in transplantation
**作者**：Bates EE, et al.
**摘要**：研究评估了重组CD83蛋白在小鼠器官移植模型中的免疫调节作用，表明其通过诱导调节性T细胞(Treg)扩增和抑制同种异体反应性T细胞激活，显著延长移植物的存活时间。
3. **文献名称**：Structural and functional characterization of the CD83 ectodomain
**作者**：Hock BD, et al.
**摘要**：该文献解析了CD83重组蛋白的晶体结构，并验证其功能表位区域，揭示了其通过Ig样结构域介导免疫细胞间信号传递的分子机制，为靶向CD83的免疫治疗提供结构基础。
*注：以上文献信息基于公开研究整合，具体引用时建议通过PubMed或期刊数据库核对原文细节。*
CD83. a transmembrane glycoprotein belonging to the immunoglobulin superfamily, is primarily expressed on the surface of activated dendritic cells (DCs), which are critical antigen-presenting cells in adaptive immunity. First identified in the 1990s, CD83 has been extensively studied for its role in immune regulation. It functions as a co-stimulatory molecule during DC-T cell interactions, promoting T cell activation and survival. However, its exact mechanistic pathways remain partially understood. Soluble forms of CD83 (sCD83) generated through proteolytic cleavage or alternative splicing exhibit immunomodulatory properties, suggesting dual roles in immune activation and suppression depending on context.
Recombinant CD83 protein, produced via expression systems like mammalian cells (e.g., HEK293 or CHO cells) or prokaryotic systems, enables controlled study of its structural and functional characteristics. Mammalian systems are preferred for preserving native glycosylation patterns critical for ligand interactions. Research highlights its therapeutic potential in autoimmune diseases (e.g., multiple sclerosis, rheumatoid arthritis) and transplantation, where sCD83 suppresses pathogenic immune responses by modulating DC maturation and regulatory T cell expansion. Conversely, membrane-bound CD83 may enhance vaccine efficacy by strengthening DC-mediated antigen presentation.
Current studies focus on optimizing recombinant CD83 production, resolving structure-activity relationships, and evaluating clinical applications. Challenges include balancing its paradoxical pro- and anti-inflammatory effects and ensuring stability in therapeutic formulations. As a biomarker, CD83 expression levels correlate with disease progression in certain cancers and infections, broadening its diagnostic relevance. Ongoing preclinical trials continue to explore its versatility in immunotherapy, positioning CD83 as a promising yet complex target in immune-related disorders.
×
